Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs
Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs
Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.